Loading
A blood test that counts HPV DNA shed by HPV-driven throat and anal cancers, used to watch for the cancer coming back; Medicare covers it in both.
NavDx, made by Naveris and owned by CareDx since 1 July 2026, measures tumour tissue modified viral HPV DNA in plasma. Medicare's MolDX programme covered it from August 2023 for surveillance of HPV-driven oropharyngeal cancer after curative-intent treatment, announced on 30 November 2023, and on 17 November 2025 extended coverage to surveillance after treated anal squamous cell carcinoma. CareDx states that it has a Medicare reimbursement rate of 1,800 dollars as an advanced diagnostic laboratory test and that more than 130,000 tests have been reported. In a study of 543 patients under surveillance for HPV-driven oropharyngeal cancer, the negative predictive value was 99.4% per test (Hanna et al., Clinical Cancer Research 2023).
Quantitative digital droplet PCR counts fragments of tumour tissue modified viral (TTMV) HPV DNA, which dying HPV-driven tumour cells shed into the blood; it identifies the most common high-risk HPV types, including 16, 18, 31, 33 and 35. No tumour sequencing is needed because the virus itself is the marker.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NavDx" OR ABSTRACT:"NavDx" OR TITLE:"TTMV-HPV DNA test" OR ABSTRACT:"TTMV-HPV DNA test" OR TITLE:"NavDx TTMV-HPV DNA" OR ABSTRACT:"NavDx TTMV-HPV DNA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NavDx, not a curated reading list.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares RaDaR ST, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/